Congratulations to the CALIPSO Trial team who started recruitment of their MRFF funded study this week February, enrolling the first 2 participants yesterday at the lead site, The Alfred.

CALIPSO (Duration of Cardiac Antimicrobial Prophylaxis Outcomes Study) is a multicentre, adaptive, pragmatic, double-blind, three-arm, placebo-controlled, randomised, non-inferiority clinical trial to compare the incidence of surgical site infection and other healthcare associated infections, health economic and microbiological impact after intraoperative only (Arm A), to 24 hours (Arm B) and, to 48 hours (Arm C) of IV cefazolin and placebo postoperative surgical antimicrobial prophylaxis in patients undergoing cardiac surgery.

Congratulations to the team in particular Chief Principal Investigator Dr Trisha Peel and CALIPSO Trial Project Team Sarah Astbury (Trial Manager) and Paige Druce (Program Manager), who have all worked hard on preparing for launch.

Research Path is a specialist at providing customised and novel tools to integrate with our feature-rich Clinical Trial Management System. If you are running a novel study and off the shelf won’t do, get in touch to see how we can support you - enquiries@researchpath.com.au.

Return to News